CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2017—MDxHealth has signed an exclusive licensing deal with Ghent University, Belgium, for its proprietary molecular diagnostic visualization technology that will allow the visual detection of epigenetic changes associated with cancer in tissue and liquid specimens. In a separate agreement, MDxHealth and the university will leverage the licensed technology for MDxHealth’s current and future in vitro diagnostic kits and laboratory-developed tests. Scientists will initially focus on validating cancer-specific biomarkers for prostate and bladder cancer.
In a separate release, MDxHealth announced it has signed a five-year agreement with Exact Sciences Corp. to share proprietary technologies from the companies’ respective discovery and development efforts in the fields of epigenetics and molecular diagnostics. Contemporaneously with the collaboration agreement, Exact Sciences will acquire MDxHealth patents directed toward colorectal cancer, including its DNA methylation biomarker, NDRG4, as well as technology covering the use of fecal immunochemical tests in combination with methylation.
MDxHealth, 866-259-5644